Total knee arthroplasty in a patient with subcutaneous and intra-articular tophaceous gout--a case report.

Total knee arthroplasty is a common operation for all types of arthritis, including chronic gouty arthritis. Tophi deposits are a well-known cause of joint destruction, but simultaneous subcutaneous and articular tophaceous gout is exceptional. We report a patient who required bilateral total knee replacement for this rare condition.

Transcultural adaptation and validation of the "Hip and Knee" questionnaire into Spanish.

BACKGROUND: The purpose of the present study is to translate and validate the "Hip and Knee Outcomes Questionnaire", developed in English, into Spanish. The 'Hip and Knee Outcomes Questionnaire is a questionnaire planned to evaluate the impact in quality of life of any problem related to the human musculoskeletal system. 10 scientific associations developed it. METHODS: The questionnaire underwent a validated translation/retro-translation process. Patients undergoing primary knee arthroplasty, before and six months postoperative, tested the final version in Spanish. Psychometric properties of feasibility, reliability, validity and sensitivity to change were assessed. Convergent validity with SF-36 and WOMAC questionnaires was evaluated. RESULTS: 316 patients were included. Feasibility: a high number of missing items in questions 3, 4 and 5 were observed. The number of patients with a missing item was 171 (51.35%) in the preoperative visit and 139 (44.0%) at the postoperative. Internal validity: revision of coefficients in the item-rest correlation recommended removing question 6 during the preoperative visit (coefficient <0.20). Convergent validity: coefficients of correlation with WOMAC and SF-36 scales confirm the questionnaire's validity. Sensitivity to change: statistically significant differences were found between the mean scores of the first visit compared to the postoperative. CONCLUSION: The proposed translation to Spanish of the 'Hip and Knee Questionnaire' is found to be reliable, valid and sensible to changes produced at the clinical practice of patients undergoing primary knee arthroplasty. However, some changes at the completion instructions are recommended. LEVEL OF EVIDENCE: Level I. Prognostic study.

Situación actual del manejo de la hemorragia digestiva alta no varicosa en España / Current management of nonvariceal upper gastrointestinal bleeding in Spain

Introducción La mortalidad en la hemorragia digestiva alta no varicosa (HDA-NV) no ha variado. Se necesita conocer más información para mejorar las estrategias de tratamiento. Los objetivos de este estudio fueron: a) describir el perfil de presentación de los episodios de HDA-NV; b) el manejo clínico según práctica clínica habitual, y c) establecer cuáles son los resultados clínicos asociados a los tratamientos endoscópicos y médicos en España. Métodos ENERGIB fue un estudio retrospectivo de cohortes que recogió información del manejo y forma de presentación de HDA-NV en Europa. Presentamos los datos relativos a España. Los pacientes se trataron según la práctica clínica habitual. Para las variables cuantitativas se calculó la media y la desviación estándar y para las categóricas se calcularon frecuencias absolutas y relativas. Resultados Los pacientes (n = 403) fueron hombres (71%), con edad media 65 años, asociaron comorbilidad (62,5%). Los equipos encargados de su manejo fueron gastroenterólogos (57,1%) o médicos internistas (25,1%). Los inhibidores de la bomba de protones se usaron de forma empírica preendoscopia en un 80% de los casos. El 6,4% presentó persistencia y el 6,7% resangrado después de la endoscopia. La tasa de mortalidad en los 30 días posteriores fue del 3,5%.ConclusionesEste estudio permite conocer el perfil de presentación de los episodios de HDA-NV en España y el manejo en práctica clínica habitual. Este se ajusta a los estándares propuestos por las recientes guías de práctica clínica. Entre otros datos destaca que los pacientes con hemorragia son cada vez de edad más avanzada y presentan un mayor número de enfermedades asociadas, lo que podría explicar que la mortalidad se haya mantenido estable a pesar de los evidentes avances en el manejo de esta entidad (AU)

Background Mortality related to nonvariceal upper gastrointestinal bleeding (NVUGIB) has not changed. More information is needed to improve the management of this entity. The aims of this study were: a) to determine the characteristics of bleeding episodes, b) to describe the clinical approaches routinely used in NVUGIB, and c) to identify adverse outcomes related to endoscopic or medical treatments in Spain. Methods The European survey of nonvariceal upper GI bleeding (ENERGiB) was an observational, retrospective cohort study on NVUGIB with endoscopic evaluation carried out across Europe. The present study focused on Spanish patients in the ENERGiB study. The patients were managed according to routine care. The mean and standard deviation were calculated for quantitative variables and absolute and relative frequencies were calculated for categorical variables. Results Patients (n=403) were mostly men (71%), with a mean age of 65 years, and co-morbidities (62.5%). Most of the patients were managed by gastroenterologists (57.1%) or internal medicine teams (25.1%). A proton pump inhibitor was used empirically in 80% before endoscopy. Bleeding persistence occurred in 6.4% and recurrence in 6.7%. The mortality rate at 30 days was 3.5%.ConclusionsThis study contributes to the characterization of Spanish patients and NVUGIB episodes in a real clinical setting and identifies the routine management of this entity, which is in line with the standards proposed by recent clinical practice guidelines. A notable finding was that age and the number of comorbidities in NVUGIB patients were increasing. These factors could explain the persistent mortality rate, despite the evident advances in the management of this entity (AU)

[Current management of nonvariceal upper gastrointestinal bleeding in Spain]. / Situación actual del manejo de la hemorragia digestiva alta no varicosa en España.

BACKGROUND: Mortality related to nonvariceal upper gastrointestinal bleeding (NVUGIB) has not changed. More information is needed to improve the management of this entity. The aims of this study were: a) to determine the characteristics of bleeding episodes, b) to describe the clinical approaches routinely used in NVUGIB, and c) to identify adverse outcomes related to endoscopic or medical treatments in Spain. METHODS: The European survey of nonvariceal upper GI bleeding (ENERGiB) was an observational, retrospective cohort study on NVUGIB with endoscopic evaluation carried out across Europe. The present study focused on Spanish patients in the ENERGiB study. The patients were managed according to routine care. The mean and standard deviation were calculated for quantitative variables and absolute and relative frequencies were calculated for categorical variables. RESULTS: Patients (n=403) were mostly men (71%), with a mean age of 65 years, and co-morbidities (62.5%). Most of the patients were managed by gastroenterologists (57.1%) or internal medicine teams (25.1%). A proton pump inhibitor was used empirically in 80% before endoscopy. Bleeding persistence occurred in 6.4% and recurrence in 6.7%. The mortality rate at 30 days was 3.5%. CONCLUSIONS: This study contributes to the characterization of Spanish patients and NVUGIB episodes in a real clinical setting and identifies the routine management of this entity, which is in line with the standards proposed by recent clinical practice guidelines. A notable finding was that age and the number of comorbidities in NVUGIB patients were increasing. These factors could explain the persistent mortality rate, despite the evident advances in the management of this entity.

Effectiveness of tranexamic acid in revision total knee arthroplasty.

The effectiveness of Tranexamic Acid (TXA, antifibrinolytic drug) in reducing allogeneic blood transfusion requirements has not been tested in revision total knee arthroplasty. The aim of this study was to assess the effectiveness of TXA after two intravenous doses of 1 g each. Between April 2006 and February 2010, 68 consecutive patients (19 male, 49 female) of 74 +/- 6 [m +/- SD] years of age were included and divided into three groups: control (28 patients), in which TXA was not administered but was not contraindicated; TXA (19 patients) who received TXA, and NO-TXA (21 patients), who were not administered TXA because of a contraindication. The proportions of patients transfused were 54%, 32% and 62% respectively in the control, TXA and NO-TXA group; the median numbers of RBC units transfused were respectively 2 [range: 1-4], 2 [range: 2-2] and 2.5 [range: 1-5], (p = 0.057). Mean total estimated blood loss was 1693 mL (SD: 689) in the control group, 1196 mL (SD: 665) in the TXA group and 2454 mL (SD: 2166) in the NO-TXA group, (p = 0.015). No adverse events were reported. TXA administration appeared as an effective and safe means of reducing blood transfusion requirements and blood loss in revision total knee arthroplasty.

Low- vs. high-pressure suction drainage after total knee arthroplasty: a double-blind randomized controlled trial.

AIM: The aim of this study was to assess the efficacy of continuous low-pressure suction drainage compared with closed high-pressure suction following total knee arthroplasty. BACKGROUND: Closed wound drainage systems are used in surgical interventions to reduce the incidence of haematomas, promote wound healing and reduce infections. However, evidence shows that using a closed wound drainage system can increase transfusion requirements. DATA SOURCES: A randomized, double-blind and parallel controlled trial was performed. Adult knee replacement patients recruited between May 2006 and March 2007 were assigned to receive low-pressure suction of 50 mmHg (experimental drainage) or high-pressure suction of 700 mmHg (comparator drainage). METHODS: The primary outcome was total blood loss after surgery. Secondary outcomes were incidence of transfusion, complications and mortality. Statistical analysis was based on an intention-to-treat approach. Linear regression was performed to account for factors that could influence blood loss. RESULTS: A total of 169 patients were included. Mean age was 73 (±6) years, 128 women and 41 men. A total of 84 patients were randomized to the experimental drainage and 85 to the comparator drainage. Analysis showed a total postoperative blood loss of 541·8 mL in the experimental group and 524·4 mL in the comparator group (P = 0·734). The only factor that showed an association with blood loss was the length of surgery. Linear regression did not show differences between the groups. CONCLUSION: Continuous low-pressure suction of 50 mmHg is not more effective than the higher aspiration pressure system to diminish the blood loss in total knee arthroplasty. The results do not support any change in current nursing practice relating to the use of this drain system.

¿Presentan un desplazamiento hacia segmentos más proximales los adenomas metacrónicos en el cáncer colorrectal? / Do metachronous colorectal adenomas show proximal shift?

ObjetivoEstudiar en el cáncer colorrectal (CCR) la posibilidad de un desplazamiento hacia segmentos más proximales de los adenomas metacrónicos tras la extirpación del tumor y sus lesiones sincrónicas.Material y métodosRevisamos 382 CCR resecados, diagnosticados y controlados evolutivamente mediante colonoscopias completas. Comparamos la localización de los adenomas metacrónicos con respecto a los sincrónicos globalmente y según el sexo, el tamaño y el número de las lesiones sincrónicas. Analizamos la frecuencia de localización exclusivamente proximal en los adenomas metacrónicos de primera, segunda y tercera generación y la comparamos con la de los adenomas sincrónicos.ResultadosUn 54,5% de los pacientes con CCR presentó adenomas sincrónicos. Tras una mediana de seguimiento de 48 meses, con 2,74±1,47 colonoscopias/caso, el 42,4% desarrolló adenomas metacrónicos, el 16,8% desarrolló adenomas de segunda generación y el 7,3% desarrolló adenomas de tercera generación. Registramos un desplazamiento proximal de los adenomas metacrónicos en ambos sexos, independientemente del tamaño y del número de las lesiones iniciales. La frecuencia de localización exclusivamente proximal de los adenomas fue sincrónico=21,2%; primera generación de metacrónicos=39,5% (p=0,0001; OR=2,46 [1,50–3,95]); segunda generación=42,6% (p=0,0008; OR=2,77 [1,44–5,31]) y tercera generación=39,3% (p=0,0003; OR=2,41 [0,97–5,93]).ConclusionesRegistramos una elevada incidencia de adenomas sincrónicos y metacrónicos. Observamos un «giro proximal» de los adenomas metacrónicos, independientemente del sexo y del tamaño y el número de las lesiones sincrónicas. Esta tendencia se mantiene en las sucesivas generaciones de adenomas metacrónicos, lo que obliga a efectuar colonoscopias completas durante todo el seguimiento postoperatorio(AU)

ObjectiveTo study the possibility of shift toward more proximal sites in colorectal cancer (CRC) after resection of tumors and synchronous lesions.Material and methodsWe reviewed 382 resected CRC diagnosed and followed-up with complete colonoscopies. The localization of metachronous adenomas was compared with that of synchronous lesions overall and by sex, tumoral size and the number of synchronous lesions. The frequency of exclusively proximal localization in first-, second- and third-generation metachronous adenomas was compared with that of synchronous adenomas.ResultsA total of 54.5% of patients with CRC had synchronous adenomas. After a median follow-up of 48 months, with 2.74±1.47 colonoscopies/case, 42.4% developed metachronous adenomas, 16.8% second-generation adenomas and 7.3% third-generation lesions. Proximal shift was found in metachronous adenomas in both sexes, independently of tumoral size and the number of initial lesions. The frequency of exclusively proximal localization in adenomas was 21.2% in synchronous lesions, 39.5% in first-generation metachronous adenomas (p=0.0001; OR=2.46 [1.50–3.95]), 42.6% in second-generation metachronous adenomas (p=0.0008; OR=2.77 [1.44–5.31]) and 39.3% in third-generation metachronous lesions (p=0.0003; OR=2.41 [0.97–5.93]).ConclusionsWe found a high incidence of synchronous and metachronous adenomas. Metachronous adenomas showed a proximal shift, independently of sex, tumoral size and the number of synchronous lesions. This tendency was maintained in successive generations of metachronous adenomas, thus demonstrating the need to perform complete colonoscopies throughout the postoperative follow-up period(AU)

[Do metachronous colorectal adenomas show proximal shift?]. / ¿Presentan un desplazamiento hacia segmentos más proximales los adenomas metacrónicos en el cáncer colorrectal?

OBJECTIVE: To study the possibility of shift toward more proximal sites in colorectal cancer (CRC) after resection of tumors and synchronous lesions. MATERIAL AND METHODS: We reviewed 382 resected CRC diagnosed and followed-up with complete colonoscopies. The localization of metachronous adenomas was compared with that of synchronous lesions overall and by sex, tumoral size and the number of synchronous lesions. The frequency of exclusively proximal localization in first-, second- and third-generation metachronous adenomas was compared with that of synchronous adenomas. RESULTS: A total of 54.5% of patients with CRC had synchronous adenomas. After a median follow-up of 48 months, with 2.74+/-1.47 colonoscopies/case, 42.4% developed metachronous adenomas, 16.8% second-generation adenomas and 7.3% third-generation lesions. Proximal shift was found in metachronous adenomas in both sexes, independently of tumoral size and the number of initial lesions. The frequency of exclusively proximal localization in adenomas was 21.2% in synchronous lesions, 39.5% in first-generation metachronous adenomas (p=0.0001; OR=2.46 [1.50-3.95]), 42.6% in second-generation metachronous adenomas (p=0.0008; OR=2.77 [1.44-5.31]) and 39.3% in third-generation metachronous lesions (p=0.0003; OR=2.41 [0.97-5.93]). CONCLUSIONS: We found a high incidence of synchronous and metachronous adenomas. Metachronous adenomas showed a proximal shift, independently of sex, tumoral size and the number of synchronous lesions. This tendency was maintained in successive generations of metachronous adenomas, thus demonstrating the need to perform complete colonoscopies throughout the postoperative follow-up period.

[Analysis of the clinical benefits and cost-effectiveness of performing a systematic second-look gastroscopy in benign gastric ulcer]. / Estudio del beneficio clínico y de coste-efectividad tras efectuar sistemáticamente una segunda gastroscopia en la úlcera gástrica benigna.

INTRODUCTION: We analyzed the need to routinely perform a second gastroscopy after an initial diagnosis of benign gastric ulcer. METHOD: A total of 226 consecutive cases of gastric ulcer were reviewed. Sensitivity (S), specificity (Sp), positive and negative predictive value (PPV and NPV) and the accuracy of the initial gastroscopy plus biopsy were analyzed, both overall and according to the initial endoscopist's experience (attending or resident physician). The diagnostic accuracy of the initial and second-look gastroscopies was compared. The number of second endoscopies required to diagnose a new case of malignant gastric ulcer and their cost was calculated, both overall and according to the endoscopist's experience. RESULTS: There were 178 benign ulcers (79%) and 48 malignant ulcers (21%). The initial gastroscopy (S: 87.2%; Sp: 100%; PPV: 100%; PNV: 96.7%; accuracy: 96.7%) was performed by an attending physician in 74% of the patients and by a resident physician in the remaining 26%. Diagnostic accuracy was higher for attending physicians than for residents (98.2% vs. 94.8%; p=0.18). The accuracy of second-look endoscopy was 100%, with a significant improvement when compared with the initial procedure (p=0.035). Three new cases of MALT lymphoma and three new cases of gastric adenocarcinoma were diagnosed and could be treated with curative intent. The number of second gastroscopies required to diagnose a new case of malignant gastric ulcer and their economic cost was: 37.3 (4,675 Euros) for the whole group, 55.2 (6,845 Euros) for attending physicians and 19.3 (2,393 Euros) for residents. CONCLUSIONS: Initial gastroscopy showed high diagnostic accuracy, which was slightly lower when performed by resident physicians. Second-look gastroscopy significantly improved the results, confirming the clinical benefit of this procedure in diagnosing potentially curable malignant lesions. The mean cost of each new diagnosis of malignancy was 4,675 Euros, which was three times lower if the initial gastroscopy was performed by a less experienced endoscopist.

Estudio del beneficio clínico y de coste-efectividad tras efectuar sistemáticamente una segunda gastroscopia en la úlcera gástrica benigna / Analysis of the clinical benefits and cost-effectiveness of performing a systematic second-look gastroscopy in benign gastric ulcer

Introducción: se discute la necesidad de efectuar sistemáticamente una segunda gastroscopia de control tras el diagnóstico inicial de una úlcera gástrica benigna. Método: revisamos 226 casos consecutivos de úlcera gástrica. Analizamos la sensibilidad (S), la especificidad (E), el valor predictivo positivo y negativo (VPP, VPN) y la precisión de la primera exploración: gastroscopia con biopsias, de modo global y según la experiencia del primer explorador (médico de plantilla o MIR). Comparamos la precisión diagnóstica entre la primera y la segunda endoscopia. Calculamos el número necesario de segundas exploraciones (NNE) para diagnosticar un nuevo caso de úlcera maligna y su coste, tanto global como según la experiencia del explorador. Resultados: registramos 178 (79%) úlceras benignas y 48 (21%) malignas. La primera exploración fue efectuada por un médico de plantilla (74%) y MIR (26%): S 87,2%, E 100%, VPP 100%, VPN 96,7% y precisión 96,7%. La precisión del médico de plantilla fue superior (98,2%) a la del MIR (94,8%) (p=0,18). La segunda exploración de control tuvo una precisión del 100%, mejorando significativamente a la primera (p=0,035) y diagnosticando 3 nuevos linfomas MALT y 3 carcinomas tratados con intención curativa. El NNE y el coste de un nuevo diagnóstico de lesión maligna fueron los siguientes: global, 37,3 (4.675 euros); médico de plantilla, 55,2 (6.845 euros), y MIR, 19,3 (2.393 euros). Conclusiones: la primera exploración obtuvo una elevada precisión diagnóstica, ligeramente menor para los MIR. La segunda endoscopia de control mejora significativamente los resultados, confirmando su beneficio clínico al diagnosticar lesiones malignas potencialmente curables. El coste medio de cada nuevo diagnóstico de malignidad ascendió a 4.675 euros, siendo 3 veces inferior si la primera exploración la efectúa un médico con menos experiencia(AU)

Introduction: We analyzed the need to routinely perform a second gastroscopy after an initial diagnosis of benign gastric ulcer. Method: A total of 226 consecutive cases of gastric ulcer were reviewed. Sensitivity (S), specificity (Sp), positive and negative predictive value (PPV and NPV) and the accuracy of the initial gastroscopy plus biopsy were analyzed, both overall and according to the initial endoscopist's experience (attending or resident physician). The diagnostic accuracy of the initial and second-look gastroscopies was compared. The number of second endoscopies required to diagnose a new case of malignant gastric ulcer and their cost was calculated, both overall and according to the endoscopist's experience. Results: There were 178 benign ulcers (79%) and 48 malignant ulcers (21%). The initial gastroscopy (S: 87.2%; Sp: 100%; PPV: 100%; PNV: 96.7%; accuracy: 96.7%) was performed by an attending physician in 74% of the patients and by a resident physician in the remaining 26%. Diagnostic accuracy was higher for attending physicians than for residents (98.2% vs. 94.8%; p=0.18). The accuracy of second-look endoscopy was 100%, with a significant improvement when compared with the initial procedure (p=0.035). Three new cases of MALT lymphoma and three new cases of gastric adenocarcinoma were diagnosed and could be treated with curative intent. The number of second gastroscopies required to diagnose a new case of malignant gastric ulcer and their economic cost was: 37.3 (4,675 Euros) for the whole group, 55.2 (6,845 Euros) for attending physicians and 19.3 (2,393 Euros) for residents(AU)

Conclusions: Initial gastroscopy showed high diagnostic accuracy, which was slightly lower when performed by resident physicians. Second-look gastroscopy significantly improved the results, confirming the clinical benefit of this procedure in diagnosing potentially curable malignant lesions. The mean cost of each new diagnosis of malignancy was 4,675 Euros, which was three times lower if the initial gastroscopy was performed by a less experienced endoscopist(AU)

[Upper gastrointestinal bleeding secondary to Dieulafoy's lesion: differential features]. / Presenta características diferenciales la hemorragia digestiva alta por lesión de Dieulafoy?

OBJECTIVE: To analyze the possible differential features of upper gastrointestinal (GI) bleeding due to Dieulafoy's lesion (DL) compared with bleeding due to gastroduodenal ulcer. MATERIAL AND METHODS: We evaluated variables associated with patient characteristics, hemorrhagic characteristics and clinical severity in 31 cases of bleeding secondary to DL and 31 cases of gastroduodenal ulcer bleeding. Univariate and multivariate statistical analysis were performed. RESULTS: The comorbidity rate was 80% in the DL group and 42% in the ulcer group (OR = 5.54; 95%CI, 1.5-20.7; p < 0.0004). Lesion location was gastric in 87% of DL versus 39% of ulcers (OR = 10.7; 95%CI, 2.6-47.6; p < 0.0003). More than one gastroscopy was required for diagnosis in 30% of DL vs. 3.2% of ulcers (OR = 12.9; 95%CI, 1.4-291; p < 0.01). Endoscopic treatment was required in 97% of DL and 39% of ulcers (OR = 47.5; 95%CI, 5.5-106.1; p < 0.0001). Active bleeding during endoscopy was registered in 81% of DL and in 29% of ulcers (OR = 10.2; 95%CI, 2.7-40.3; p < 0.0005). The remaining variables analyzed showed no significant differences. The mortality rate was 9.7% in the DL group and 3.2% in the ulcer group (p = NS). Multivariate analysis showed that gastric location (p < 0.01), active bleeding (p < 0.01), and comorbidity (p < 0.02) were more frequent in DL. CONCLUSIONS: Active bleeding and gastric location of the lesion were more frequent in the DL group than in the ulcer group. Diagnosis of DL is difficult, requiring a greater number of gastroscopies. Initial hemorrhage severity and the success rate of endoscopic treatment were similar in the two groups. The higher mortality found in DL can be explained by the greater comorbidity in these patients, with a worse bleeding tolerance.

¿Presenta características diferenciales la hemorragia digestiva alta por lesión de Dieulafoy? / Upper gastrointestinal bleeding secondary to Dieulafoy’s lesion: differential features

Objetivo: Analizar la presencia de posibles rasgos diferenciales de la hemorragia digestiva alta (HDA) por lesión de Dieulafoy (LD), comparándola con el sangrado por úlcera gastroduodenal. Material y métodos: Evaluamos los parámetros referentes a las características de los pacientes, de la hemorragia y de la gravedad clínica en 31 casos de hemorragia por LD y 31 por úlcera gastroduodenal. Se efectuó un análisis comparativo univarinate y multivariante entre ambos grupos. Resultados: El índice de comorbilidad fue del 80% en LD y del 42% en la úlcera (odds ratio [OR] = 5,54; intervalo de confianza del 95%, 1,5-20,7; p < 0,0004). La localización de la lesión fue gástrica en el 87% de las LD y en el 39% de las úlceras (OR = 10,7; IC del 95%, 2,6-47,6; p < 0,0003). Se precisó más de una gastroscopia para llegar al diagnóstico en el 30% de LD frente al 3,2% de las úlceras (OR = 12,9; IC del 95%, 1,4-291; p < 0,01). Fue necesario aplicar tratamiento endoscópico en el 97% de las LD frente al 39% de las úlceras (OR = 47,5; IC del 95%, 5,5-106,1; p < 0,0001). Se registró un sangrado activo durante la endoscopia en el 81% de las LD frente al 29% de las úlceras (OR = 10,2; IC del 95%, 2,7-40,3; p < 0,0005). El resto de los parámetros analizados no mostró diferencias significativas. La tasa de mortalidad fue del 9,7% en las LD frente al 3,2% en las úlceras (p = no significativo). En el análisis multivariante, la localización gástrica de la lesión (p < 0,01), el sangrado activo (p < 0,01) y la comorbilidad (p < 0,02) fueron superiores en la LD. Conclusiones: En la LD, la localización gástrica y el sangrado activo son hallazgos más frecuentes que en el grupo ulceroso. El diagnóstico de LD es más difícil, ya que requiere un mayor número de gastroscopias. La gravedad inicial de la hemorragia y el éxito del tratamiento endoscópico son similares en ambos grupos. La mayor mortalidad encontrada en las LD podría explicarse por la mayor comorbilidad de estos pacientes, con una peor tolerancia al sangrado

Objective: To analyze the possible differential features of upper gastrointestinal (GI) bleeding due to Dieulafoy’s lesion (DL) compared with bleeding due to gastroduodenal ulcer. Material and methods: We evaluated variables associated with patient characteristics, hemorrhagic characteristics and clinical severity in 31 cases of bleeding secondary to DL and 31 cases of gastroduodenal ulcer bleeding. Univariate and multivariate statistical analysis were performed. Results: The comorbidity rate was 80% in the DL group and 42% in the ulcer group (OR = 5.54; 95%CI, 1.5-20.7; p < 0.0004). Lesion location was gastric in 87% of DL versus 39% of ulcers (OR = 10.7; 95%CI, 2.6-47.6; p < 0.0003). More than one gastroscopy was required for diagnosis in 30% of DL vs. 3.2% of ulcers (OR = 12.9; 95%CI, 1.4-291; p < 0.01). Endoscopic treatment was required in 97% of DL and 39% of ulcers (OR = 47.5; 95%CI, 5.5-106.1; p < 0.0001). Active bleeding during endoscopy was registered in 81% of DL and in 29% of ulcers (OR = 10.2; 95%CI, 2.7-40.3; p < 0.0005). The remaining variables analyzed showed no significant differences. The mortality rate was 9.7% in the DL group and 3.2% in the ulcer group (p = NS). Multivariate analysis showed that gastric location (p < 0.01), active bleeding (p < 0.01), and comorbidity (p < 0.02) were more frequent in DL. Conclusions: Active bleeding and gastric location of the lesion were more frequent in the DL group than in the ulcer group. Diagnosis of DL is difficult, requiring a greater number of gastroscopies. Initial hemorrhage severity and the success rate of endoscopic treatment were similar in the two groups. The higher mortality found in DL can be explained by the greater comorbidity in these patients, with a worse bleeding tolerance

[Gastric plasmacytoma as an uncommon cause of upper gastrointestinal bleeding]. / Plasmocitoma gástrico como causa infrecuente de hemorragia digestiva alta.

Gastric plasmacytoma is an infrequent form of presentation of monoclonal gammopathy that, if ulcerated, can cause upper gastrointestinal bleeding. This entity is usually localized but may progress to multiple myeloma or other forms of monoclonal gammopathy. Differential diagnosis should be performed with other monoclonal gammopathies, based on laboratory and histological criteria, as well as with other gastric tumors such as adenocarcinoma, gastrointestinal stromal tumors, neuroendocrine tumors and lymphomas. Differential diagnosis can be based on radiological and endoscopic characteristics, although definitive diagnosis will undoubtedly be based on histological study and immunohistochemical techniques. We describe the case of a male patient who underwent investigations for upper gastrointestinal bleeding and iron deficiency anemia. The final diagnosis was multiple myeloma associated with gastric plasmacytoma.

Plasmocitoma gástrico como causa infrecuente de hemorragia digestiva alta / Gastric plasmacytoma as an uncommon cause of upper gastrointestinal bleeding

El plasmocitoma gástrico es una forma rara de presentación de las gammapatías monoclonales, y puede ser una causa de hemorragia digestiva alta si se encuentra ulcerado. Suele ser localizado, pero puede evolucionar hacia un mieloma múltiple u otras formas de gammapatía monoclonal. El diagnóstico diferencial hay que hacerlo con otras gammapatías monoclonales, basándose en criterios analíticos e histológicos, y con otros tumores gástricos, como el adenocarcinoma, los tumores de la estroma gastrointestinal, los tumores neuroendocrinos y los linfomas. Para ello, nos podemos basar en las diferentes características radiológicas y endoscópicas, aunque, sin duda, el estudio histológico y las técnicas inmunohistoquímicas establecerán el diagnóstico definitivo. En esta observación clínica se describe el caso de un paciente que presentaba una hemorragia digestiva alta y una anemia ferropénica, con diagnóstico final de mieloma múltiple asociado a plasmocitoma gástrico

Gastric plasmacytoma is an infrequent form of presentation of monoclonal gammopathy that, if ulcerated, can cause upper gastrointestinal bleeding. This entity is usually localized but may progress to multiple myeloma or other forms of monoclonal gammopathy. Differential diagnosis should be performed with other monoclonal gammopathies, based on laboratory and histological criteria, as well as with other gastric tumors such as adenocarcinoma, gastrointestinal stromal tumors, neuroendocrine tumors and lymphomas. Differential diagnosis can be based on radiological and endoscopic characteristics, although definitive diagnosis will undoubtedly be based on histological study and immunohistochemical techniques. We describe the case of a male patient who underwent investigations for upper gastrointestinal bleeding and iron deficiency anemia. The final diagnosis was multiple myeloma associated with gastric plasmacytoma

[High incidence rates of inflammatory bowel disease in Navarra (Spain). Results of a prospective, population-based study]. / Altas tasas de incidencia de enfermedad inflamatoria intestinal en Navarra. Resultados de un estudio prospectivo y poblacional.

INTRODUCTION: As reflected in the European Collaborative Study on Inflammatory Bowel Disease (1991-1993), differences between northern and southern European countries in the incidence of ulcerative colitis (UC) and Crohn's disease (CD) show a tendency to decrease. No data are available on the current incidence of these diseases in Navarre (northern Spain). AIM: To determine the present incidence of inflammatory bowel disease (IBD) in Navarra. PATIENTS AND METHODS: A prospective, population-based study was performed to determine the incidence of IBD in Navarra between 2001 and 2003. Total population: 569,628 inhabitants (284,620 males). All cases of IBD diagnosed in any public or private hospital in Navarre were included in the study. Crude rates and age- and sex-specific rates adjusted to the European standard population were calculated. RESULTS: A total of 288 cases were diagnosed (UC 176, CD 102, indeterminate colitis 10). Crude rates of UC, CD and indeterminate colitis were 10.29, 5.96 and 0.58 cases/100,000 inhabitants/year respectively (the population aged 0-14 years of age was included). Specific rates were 9.57 (95% CI, 7.27-12.57) and 5.85 (95% CI, 3.99-8.14) cases/100,000 inhabitants/year for UC and CD, respectively. CONCLUSIONS: The incidence of UC and CD in Navarra has increased in the last decade, with rates close to those of northern European countries and higher than those recently published in Spanish prospective studies.

Altas tasas de incidencia de enfermedad inflamatoria intestinal en Navarra. Resultados de un estudio prospectivo y poblacional / High incidence rates of inflammatory bowel disese in Navarra (Spain). Results of a prospective, population-based study

INTRODUCCIÓN: Tal como se reflejó en el Estudio CooperativoEuropeo del período 1991-1993, tienden a reducirse lasdiferencias norte/sur en las tasas de incidencia de colitis ulcerosa(CU) y enfermedad de Crohn (EC). No hay estudiosque hayan actualizado el estado de la cuestión en Navarra.OBJETIVOS: Nos planteamos conocer la incidencia actual dela enfermedad inflamatoria intestinal (EII) en Navarra.PACIENTES Y MÉTODOS: Estudio prospectivo y poblacional dela incidencia de EII en Navarra en el período 2001-2003, enuna población de 569.628 habitantes (284.620 varones). Serecogen la totalidad de los casos diagnosticados en todos loscentros públicos y privados de Navarra con capacidad dediagnosticar una EII. Se calculan las tasas crudas y las tasasespecíficas ajustadas a la población estándar europea.RESULTADOS: Se diagnosticaron 288 casos (176 CU, 102 EC y10 colitis indeterminadas [CI]). Las tasas crudas para CU,EC y CI fueron de 10,29, 5,96 y 0,58 casos/100.000 habitantes/año, respectivamente (incluida la población de 0-14 añosde edad). Las tasas específicas (intervalo de confianza del95%) fueron de 9,57 (7,27-12,57) y 5,85 (3,99-8,14) casos/100.000 habitantes/año para CU y EC, respectivamente.CONCLUSIONES: La incidencia de CU y EC en Navarra haaumentado en la última década, con tasas cercanas a las referidasen los países del norte de Europa y algo superiores alas de los últimos estudios prospectivos españoles

INTRODUCTION: As reflected in the European Collaborative Study on Inflammatory Bowel Disease (1991-1993), differencesbetween northern and southern European countries in theincidence of ulcerative colitis (UC) and Crohn’s disease (CD)show a tendency to decrease. No data are available on the currentincidence of these diseases in Navarre (northern Spain).AIM: To determine the present incidence of inflammatorybowel disease (IBD) in Navarra.PATIENTS AND METHODS: A prospective, population-basedstudy was performed to determine the incidence of IBD inNavarra between 2001 and 2003. Total population: 569,628inhabitants (284,620 males). All cases of IBD diagnosed inany public or private hospital in Navarre were included inthe study. Crude rates and age- and sex-specific rates adjustedto the European standard population were calculated.RESULTS: A total of 288 cases were diagnosed (UC 176, CD102, indeterminate colitis 10). Crude rates of UC, CD andindeterminate colitis were 10.29, 5.96 and 0.58 cases/100,000inhabitants/year respectively (the population aged 0-14 yearsof age was included). Specific rates were 9.57 (95% CI,7.27-12.57) and 5.85 (95% CI, 3.99-8.14) cases/100,000 inhabitants/year for UC and CD, respectively.CONCLUSIONS: The incidence of UC and CD in Navarra hasincreased in the last decade, with rates close to those of northernEuropean countries and higher than those recently published in Spanish prospective studies (AU)